OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 2.

Table. 2.

Comparison of SARS-CoV-2 antibody assays using 10 seroconversion panels

Seroconversion panel CLIA EIA


Abbott Siemens Roche Euroimmun Vircell BioRad







Patient N (Days) IgG Total Total IgA IgG IgM+IgA IgG Total
1 9 (7–30) 7/9 (11)* 7/9 (11) 7/9 (11) 7/9 (11) 7/9 (11) 9/9 (7) 7/9 (11) 9/9 (7)
2 8 (6–21) 5/8 (10) 5/8 (10) 5/8 (10) 6/8 (9) 4/8 (12) 5/8 (10) 5/8 (10) 7/8 (8)
3 11 (9–30) 7/11 (16) 5/11 (18) 5/11 (18) 5/11 (18) 5/11 (18) 1/11 (28) 5/11 (18) 6/11 (17)
4 7 (3–15) 7/7 (3) 2/7 (10) 6/7 (5) 1/7 (15) 2/7 (10) 7/7 (3) 7/7 (3) 7/7 (3)
5 8 (12–32) 6/8 (16) 7/8 (14) 7/8 (14) 8/8 (12) 7/8 (14) 7/8 (14) 7/8 (14) 8/8 (12)
6 7 (10–24) 6/7 (11) 2/7 (18) 6/7 (11) 7/7 (10) 1/7 (24) 6/7 (11) 7/7 (10) 7/7 (10)
7 7 (9–23) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9) 5/7 (11) 7/7 (9) 7/7 (9) 7/7 (9)
8 5 (5–31) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11)
9 5 (5–33) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14)
10 8 (5–25) 0/8 ( > 25) 0/8 ( > 25) 0/8 ( > 25) 6/8 (9) 4/8 (14) 6/8 (9) 4/8 (14) 6/8 (9)
Total 75 53/75 43/75 51/75 55/75 43/75 56/75 57/75 65/75
70.7% 57.3% 68.0% 73.3% 57.3% 74.7% 76.0% 86.7%
Seroconversion panel LFIA sVNT


Boditech Med SD biosensor PCL Sugentech Rapigen GenScript







Patient N (Days) IgM IgG IgM IgG IgM IgG IgM IgG IgM IgG IgG
1 9 (7–30) 8/9 (9) 7/9 (11) 9/9 (7) 6/9 (14) 8/9 (9) 7/9 (11) 9/9 (7) 6/9 (14) 8/9 (9) 7/9 (11) 7/9 (11)
2 8 (6–21) 5/8 (10) 5/8 (10) 6/8 (9) 6/8 (9) 5/8 (10) 5/8 (10) 7/8 (8) 6/8 (9) 6/8 (9) 6/8 (9) 5/8 (10)
3 11 (9–30) 6/11 (17) 6/11 (17) 6/11 (17) 6/11 (17) 5/11 (18) 4/11 (22) 7/11 (16) 4/11 (22) 6/11 (17) 4/11 (22) 7/11 (16)
4 7 (3–15) 7/7 (3) 6/7 (5) 6/7 (5) 6/7 (5) 6/7 (5) 1/7 (12) 7/7 (3) 6/7 (5) 6/7 (5) 6/7 (5) 5/7 (6)
5 8 (12–32) 8/8 (12) 8/8 (12) 8/8 (12) 6/8 (16) 8/8 (12) 7/8 (14) 8/8 (12) 6/8 (16) 8/8 (12) 6/8 (16) 8/8 (12)
6 7 (10–24) 7/7 (10) 6/7 (11) 7/7 (10) 6/7 (11) 7/7 (10) 5/7 (12) 7/7 (10) 6/7 (11) 7/7 (10) 7/7 (10) 7/7 (10)
7 7 (9–23) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9) 7/7 (9)
8 5 (5–31) 0/5 ( > 31) 4/5 (11) 4/5 (11) 5/5 (5) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11) 4/5 (11)
9 5 (5–33) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14) 4/5 (14)
10 8 (5–25) 5/8 (11) 3/8 (18) 5/8 (11) 1/8 (25) 5/8 (11) 4/8 (14) 6/8 (9) 1/8 (25) 5/8 (11) 3/8 (25) 4/8 (14)
Total 75 57/75 56/75 62/75 53/75 59/75 48/75 66/75 50/75 61/75 54/75 58/75
76.0% 74.7% 82.7% 70.7% 78.7% 64.0% 88.0% 66.7% 81.3% 72.0% 77.3%

*Data represent numbers of positive bleeds/number of serial bleeds tested (initial positive day from symptom onset).

Abbreviations: N, number of samples; CLIA, chemiluminescence immunoassay; EIA, enzyme immunoassay; LFIA, lateral flow immunoassay; sVNT, surrogate virus neutralization test.

Ann Lab Med 2021;41:577~587 https://doi.org/10.3343/alm.2021.41.6.577

© Ann Lab Med